Q-omics provides the consensus-scored XRRA1 profile across patient tissues and cancer cell-line models. XRRA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, XRRA1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, XRRA1 RNA expression shows 17,343 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KICH, and HNSC as cancer lineages where XRRA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XRRA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XRRA1 survival associations across molecular data types. XRRA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XRRA1 RNA expression–survival associations across cancer types. High XRRA1 expression shows unfavorable associations in KICH, CESC and UVM, but favorable associations in UCS, KIRC and BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KICH as the clearest survival context for XRRA1 RNA expression.
This table summarizes XRRA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for XRRA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XRRA1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, LUAD, BRCA and CHOL. The HNSC box plot shows higher XRRA1 RNA expression in tumor versus normal tissue (log2 FC = +0.656, t-test p < 0.001).
This table shows molecular features associated with XRRA1 in patient tissues and cancer cell lines. In patient samples, XRRA1 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set. In cancer cell lines, XRRA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
